SCHEMBL7380938

SCHEMBL7380938

CCOC(=O)c1csc(-c2ccc(C)c3ccccc23)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.56
NPC1 O15118 7/20 0.56
MAPT P10636 5/20 0.56
POLB P06746 1/20 0.56
PKM P14618 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
RXFP1 Q9HBX9 1/20 0.56
ALDH1A1 P00352 2/20 0.54
GAA P10253 3/20 0.53
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
CYP1A2 P05177 2/20 0.50
CYP2C19 P33261 1/20 0.50
CLK1 P49759 1/20 0.47
CYP19A1 P11511 1/20 0.47
LMNA P02545 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
MAOA P21397 1/20 0.46
ACHE P22303 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7675971 0.88 MAPT (0.56) RAB9ANPC1MAPTPOLBPKM
SCHEMBL6983909 0.87 RAB9A (0.56) RAB9ANPC1MAPTPOLBPKM
SCHEMBL15754817 0.85 RAB9A (0.60) RAB9ANPC1MAPTPOLBPKM
Dimethylamine SCHEMBL7678579 0.83 RAB9A (0.50) RAB9ANPC1MAPTPOLBPKM
SCHEMBL7384817 0.83 RAB9A (0.50) RAB9ANPC1MAPTPOLBPKM
SCHEMBL13548675 0.82 RAB9A (0.56) RAB9ANPC1MAPTPOLBPKM
SCHEMBL13144514 0.81 MAPT (0.70) RAB9ANPC1MAPTPOLBPKM
SCHEMBL2551417 0.81 HTR2B (0.61) RAB9ANPC1MAPTPOLBPKM
SCHEMBL6224829 0.81 RAB9A (0.61) RAB9ANPC1MAPTPOLBPKM
SCHEMBL2080725 0.81 RAB9A (0.68) RAB9ANPC1MAPTPOLBPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1019046-A4 PROTEASE INHIBITORS SMITHKLINE BEECHAM (US) 2002-11-27 EP disclosed
US-20020049316-A1 Protease inhibitors HALBERT STACIE MARIE (US) 2002-04-25 US disclosed
EP-1019046-A1 PROTEASE INHIBITORS Smithkline Beecham (US) 2000-07-19 EP disclosed
WO-1998048799-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1998-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049316-A1 Protease inhibitors CTSK, CTSZ, CTSG RAB9A 827/4885NPC1 614/4885MAPT 796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.